News & Updates | SOLVE FSHD

07/12/23Press Release

SOLVE FSHD Announces New Collaborative Research Grants to Accelerate Novel Potential Therapeutics for Facioscapulohumeral Muscular Dystrophy (FSHD)

04/19/23Press Release

SOLVE FSHD invests in Epic Bio for the development of a novel treatment for Facioscapulohumeral Muscular Dystrophy

10/15/22Press Release

SOLVE FSHD Invests Up To US $10 Million in Vita Therapeutics

10/12/22Press Release

SOLVE FSHD Invests US $1 Million in miRecule to Accelerate Development of Best-in-Class Antibody-RNA Conjugate to Treat Facioscapulohumeral Muscular Dystrophy

09/22/22Press Release

SOLVE FSHD Invests US$3 Million in Altay Therapeutics

09/20/22News

SOLVE FSHD Provides Funding to n-Lorem for a Collaboration to Expand Understanding of FSHD2, a Rare Form of Muscular Dystrophy

06/08/22News

SOLVE FSHD Announces Appointment of Executive Director Dr. Eva Chin and Venture-Philanthropic Funding Structure

03/11/22Press Release

SOLVE FSHD is supporting the FSHD Clinical Trial Research Network (CTRN) through a donation of $2.8M to the FSHD Canada Foundation